fidanacogene elaparvovec

Details

Files
Generic Name:
fidanacogene elaparvovec
Project Status:
Complete
Therapeutic Area:
Hemophilia B
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Beqvez
Project Line:
Reimbursement Review
Project Number:
SG0802-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adults (aged 18 years or older) with moderately severe to severe Hemophilia B (congenital Factor IX deficiency) who are negative for neutralizing antibodies to variant AAV serotype Rh74.
Submission Type:
Initial
Fee Schedule:
Schedule E
Indications:
Beqvez (fidanacogene elaparvovec) is an adeno-associated viral (AAV) vector-based gene therapy indicated for the treatment of adults (aged 18 years or older) with moderately severe to severe Hemophilia B (congenital Factor IX deficiency) who are negative for neutralizing antibodies to variant AAV serotype Rh74
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openJune 20, 2023
Call for patient/clinician input closedAugust 14, 2023
Clarification:

- Patient input submission received from Canadian Hemophilia Society (CHS)

Submission receivedAugust 01, 2023
Submission acceptedAugust 16, 2023
Review initiatedAugust 17, 2023
Draft CADTH review report(s) provided to sponsor for commentNovember 02, 2023
Deadline for sponsors commentsNovember 14, 2023
CADTH review report(s) and responses to comments provided to sponsorDecember 08, 2023
Expert committee meeting (initial)December 20, 2023
Draft recommendation issued to sponsorJanuary 11, 2024
Draft recommendation posted for stakeholder feedbackJanuary 18, 2024
End of feedback periodFebruary 02, 2024
Final recommendation postedMarch 06, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)March 04, 2024
CADTH review report(s) postedJune 05, 2024